MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from maturitiesand sales of...$316,180K Proceeds from issuance ofcommon stock via...$1,080K Proceeds from issuance ofcommon stock through...$524K Net cash provided by(used in) investing...$192,799K Net cash provided byfinancing activities$1,604K Canceled cashflow$123,381K Net decrease incash, cash...-$41,052K Canceled cashflow$194,403K Stock compensationexpense$62,419K Depreciation expense$3,557K Impairment of intangibleasset$2,300K Prepaid expenses andother current assets-$1,612K Loss on disposal ofproperty and equipment-$1,003K Purchases of investments$122,971K Purchases of property andequipment$410K Net cash used inoperating activities-$235,455K Canceled cashflow$70,891K Net loss-$276,479K Accounts payable andaccrued expenses-$11,440K Deferred revenue-$7,679K Net amortization ofpremiums and discounts on...$4,949K Operating lease assets andliabilities, net$4,272K Other liabilities-$1,527K
Cash Flow
source: myfinsight.com

Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics, Inc. (RLAY)